TY - JOUR
T1 - Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
T2 - JACC Guideline Comparison
AU - Kelsey, Michelle D.
AU - Nelson, Adam J.
AU - Green, Jennifer B.
AU - Granger, Christopher B.
AU - Peterson, Eric D.
AU - McGuire, Darren K.
AU - Pagidipati, Neha J.
N1 - Publisher Copyright:
© 2022 American College of Cardiology Foundation
PY - 2022/5/10
Y1 - 2022/5/10
N2 - Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor management, with blood pressure and low-density lipoprotein-cholesterol treatment, glycemic control, kidney protection, and lifestyle intervention. There are several recommendation and guideline documents across cardiology, endocrinology, nephrology, and general medicine professional societies from the United States and Europe with recommendations for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Although there are some noteworthy differences, particularly in risk stratification, low-density lipoprotein-cholesterol and blood pressure treatment targets, and the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, overall there is considerable alignment across recommendations from different professional societies.
AB - Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor management, with blood pressure and low-density lipoprotein-cholesterol treatment, glycemic control, kidney protection, and lifestyle intervention. There are several recommendation and guideline documents across cardiology, endocrinology, nephrology, and general medicine professional societies from the United States and Europe with recommendations for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Although there are some noteworthy differences, particularly in risk stratification, low-density lipoprotein-cholesterol and blood pressure treatment targets, and the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, overall there is considerable alignment across recommendations from different professional societies.
KW - guidelines
KW - prevention
KW - type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85129374141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129374141&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2022.02.046
DO - 10.1016/j.jacc.2022.02.046
M3 - Review article
C2 - 35512864
AN - SCOPUS:85129374141
SN - 0735-1097
VL - 79
SP - 1849
EP - 1857
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 18
ER -